HC Wainwright & Co. Maintains Buy on Heron Therapeutics, Lowers Price Target to $2
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Brandon Folkes maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $2.
HC Wainwright & Co. analyst Brandon Folkes maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $2.